A 38-year-old who notices blood in the stool might blame hemorrhoids. A 44-year-old with persistent cramping might chalk it up to stress. But federal mortality data now show that colorectal cancer has become the deadliest cancer for Americans under 50, a shift that has unfolded over roughly two decades and caught much of the medical establishment off guard.
The disease ranked fourth among cancer killers in this age group during the late 1990s. By the time the American Cancer Society published its 2024 cancer statistics report (the most recent published annual report, released in January 2024), colorectal cancer had climbed to the No. 1 cause of cancer death for men under 50 and the No. 2 cause for women in the same age range, trailing only breast cancer. During the same period, death rates from lung cancer and several other common tumors fell among younger adults, making colorectal cancer’s rise all the more striking.
The numbers behind the shift
A research letter by Siegel and colleagues, published in JAMA in 2024, quantified the trend using National Center for Health Statistics death-certificate data from 1990 through 2023. The researchers used the National Cancer Institute’s SEER*Stat platform to calculate age-standardized mortality rates and the NCI’s Joinpoint Regression Program to pinpoint when trends changed direction. Their finding: colorectal cancer mortality among adults under 50 has climbed roughly 1.1% per year since the mid-2000s, even as mortality from competing cancers declined.
Because death certificates are a near-universal administrative record in the United States, undercounting for a disease like colorectal cancer is minimal. And because the statistical tools are standardized and publicly available, the results are reproducible. The 1.1% annual increase is not an estimate from a single hospital system or a proprietary model. It comes from validated algorithms applied to a comprehensive federal dataset.
Independent context comes from the CDC’s U.S. Cancer Statistics program, which combines the National Program of Cancer Registries with SEER data to track incidence patterns, stage at diagnosis, and surveillance coverage nationwide. Separately, an Associated Press analysis of death-certificate records found that younger adults who die of colon cancer are disproportionately people with less formal education, pointing to a socioeconomic gradient in who gets diagnosed early enough to survive.
Why it is happening remains an open question
The statistical trend is well established. The biological explanation is not. Researchers have proposed several contributing factors: dietary shifts toward ultra-processed foods, rising obesity rates among people born after 1980, changes in the gut microbiome, and increased exposure to environmental carcinogens. But no large-scale, registry-linked study has isolated a single dominant driver. The honest answer, as of spring 2026, is that scientists are still working to untangle a web of overlapping risks.
That uncertainty extends to screening policy. In 2021, the U.S. Preventive Services Task Force lowered its recommended starting age for average-risk colorectal cancer screening from 50 to 45. The change was significant, but many of the deaths captured in the JAMA analysis occurred in people in their 30s and early 40s, ages the current guideline does not cover. No federal agency has publicly signaled that a further reduction in the starting age is imminent, leaving a gap between rising mortality and screening reach that is difficult to quantify.
Racial and ethnic breakdowns present another blind spot. While SEER and CDC data products offer aggregate incidence figures, detailed post-2023 demographic breakdowns by race for the under-50 population have not been released in the sources reviewed here. The education-linked disparity reported by the AP offers one lens into inequality, but education level recorded on a death certificate is an imperfect proxy for income, insurance status, or access to colonoscopy. It can also be misclassified when grieving family members provide the information.
COVID-era disruptions add yet another layer of uncertainty. Pandemic lockdowns and deferred medical visits in 2020 and 2021 delayed cancer diagnoses across the board. If patients who skipped routine care later presented with more advanced disease, that could have inflated recent mortality figures. Whether the disruption created additional deaths or simply shifted their timing has not been resolved in any primary analysis available.
Screening options, costs, and what younger adults should know
Current guidelines recommend that adults at average risk begin colorectal cancer screening at age 45. Several options exist, each with different trade-offs in sensitivity, cost, and convenience:
- Colonoscopy examines the entire colon and can remove precancerous polyps on the spot. It is typically recommended every 10 years for average-risk patients. Under the Affordable Care Act, most private insurers and Medicare cover screening colonoscopies with no out-of-pocket cost when the test is coded as preventive. However, if polyps are found and removed during the procedure, some plans may reclassify it as diagnostic, potentially leaving the patient responsible for a share of the cost. Without insurance, a colonoscopy can range from roughly $1,000 to $3,000 or more depending on the facility and region.
- Fecal immunochemical test (FIT) is a stool-based test done at home and repeated annually. It is generally covered by insurance as a preventive screening with no copay. Without insurance, the test itself typically costs $25 or less, though a positive result requires a follow-up colonoscopy.
- Multitarget stool DNA test (sold as Cologuard) is also done at home and is recommended every three years. Most insurers cover it for adults 45 and older who meet average-risk criteria. The list price without insurance is approximately $650, though manufacturer assistance programs may reduce out-of-pocket costs. A positive result likewise requires a follow-up colonoscopy.
A primary care provider can help determine which option fits a patient’s risk profile and insurance situation. People with a family history of colorectal cancer, inflammatory bowel disease, or known genetic syndromes like Lynch syndrome may need to start screening earlier and at shorter intervals. That conversation should happen well before age 45.
Symptoms that warrant prompt medical evaluation at any age include rectal bleeding, unexplained iron-deficiency anemia, persistent changes in bowel habits, and unintentional weight loss. Younger patients and their doctors sometimes attribute these signs to benign conditions, which can delay diagnosis and allow the cancer to advance.
Why screening access still depends on where you live and what you earn
The science behind the rise in early-onset colorectal cancer is still catching up to the statistics. But the data are clear enough to support a straightforward message: screening saves lives, symptoms deserve attention, and age alone should not be a reason to dismiss risk. Ensuring that access to timely screening does not depend on education, geography, or income remains one of the most urgent challenges in closing the gap.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
